MARA Holdings
MARA
Coinbase
COIN
Salesforce
CRM
Microsoft
MSFT
Apple
AAPL
US Stock MarketDetailed Quotes
INCY Incyte
- 71.500
- -0.990-1.37%
Trading Dec 12 13:44 ET
13.77BMarket Cap794.44P/E (TTM)
72.075High70.480Low541.47KVolume70.500Open72.490Pre Close38.72MTurnover0.34%Turnover Ratio26.98P/E (Static)192.65MShares83.95052wk High4.34P/B11.48BFloat Cap50.35052wk Low--Dividend TTM160.50MShs Float153.150Historical High--Div YieldTTM2.20%Amplitude1.850Historical Low71.517Avg Price1Lot Size
About Incyte Company
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Company Profile
SymbolINCY
Company NameIncyte
Listing DateNov 4, 1993
Issue Price7.50
Founded1991
CEOMr. Herve Hoppenot
MarketNASDAQ
Employees2524
Fiscal Year Ends12-31
Address1801 Augustine Cut-Off
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19803
Phone1-302-498-6700
Websitehttp://www.incyte.com
Company Executives
- Name
- Position
- Salary
- Herve Hoppenot
- Chairman of the Board, President and Chief Executive Officer
- 16.66M
- Christiana Stamoulis, M.B.A.
- Executive Vice President and Chief Financial Officer
- 5.08M
- Dr. Steven H. Stein, M.D.
- Executive Vice President and Chief Medical Officer
- 5.63M
- Thomas Tray
- Vice President and Chief Accounting Officer
- --
- Barry P. Flannelly, Pharm.D.
- Executive Vice President and General Manager, North America
- 4.09M
- Jonathan Elliott Dickinson
- Executive Vice President and General Manager, Europe
- --
- Paula J. Swain
- Executive Vice President, Human Resources
- --
- Michael James Morrissey
- Executive Vice President and Head of Global Technical Operations
- --
- Sheila A Denton
- Executive Vice President, General Counsel and Corporate Secretary
- --
- Vijay K. Iyengar
- Executive Vice President, Global Strategy and Corporate Development
- --
- Dr. Pablo J. Cagnoni, M.D.
- President and Head of Research and Development
- 15.83M
- Paul J. Clancy
- Independent Director
- 479.76K
- Julian C. Baker
- Lead Independent Director
- 512.76K
- Dr. Otis W. Brawley,M.D.
- Independent Director
- 454.76K
- Dr. Katherine A. High, M.D.
- Independent Director
- 454.76K
- Dr. Jacqualyn A. Fouse, PhD
- Independent Director
- 466.26K
- Jean-Jacques Bienaime
- Independent Director
- 478.76K
- Dr. Susanne Schaffert, PhD
- Independent Director
- 444.76K
- Dr. Edmund P. Harrigan, M.D.
- Independent Director
- 482.26K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
